|
- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
回复 nevernevermind 的帖子
这项研究多年和涉及许多患者, 因此患者的病史很复杂. 当然这项研究是非常有用的, 但理解需要仔细研究患者的数据.阅读整篇论文至关重要.
During the entire follow-up period, 296 (40.9%) patients remained treatment-
naïve, while the remaining 427 (59.1%) received antiviral therapy. Fifty (7%)
patients received antiviral therapy prior to ESC (but were not on therapy at the
time of ESC), of which 41 had interferon-based therapy, and 10 patients received
lamivudine for a limited duration. Of the 41 patients who received interferon
therapy prior to ESC, only 1 patient received pegylated interferon, and 7 patients
achieved ESC within 1 year after stopping therapy.
One hundred and sixty nine (23%) were on therapy at the time of ESC, of which
the majority was receiving lamivudine. After ESC, 231 (32%) required
commencement of antiviral therapy, of which some had already received therapy
prior to HBeAg seroclearance. There were different time-points for the
resumption of therapy, and some patients may have received more than one type
of antiviral therapy.
在整个随访期间，296例（40.9％）患者仍然没有接受治疗，
而其余的427（59.1％）接受抗病毒治疗。 五十（7％）
患者在ESC之前接受过抗病毒治疗（但在ESC的时间没有接受过治疗）
，其中41人接受了干扰素治疗，10人接受了有限时间的拉米夫定治疗
。 ESC前接受干扰素的41名患者中仅有1例患者接受聚乙二醇干扰素治疗，7例患者
停止治疗后1年内达到ESC。
在ESC的时候，有169名（23％）在接受治疗，其中包括
大多数人正在接受拉米夫定。 ESC之后，231（32％）
需要开始抗病毒治疗，其中一些已经接受过治疗
在HBeAg血清学清除之前。 恢复治疗有不同的时间点,
有些患者可能已经接受多种类型的抗病毒治疗。
在这组患者中, 有些在ESC(E抗原血清学清除)之前或之后没有治疗(49%).
一些ESC之前接受过治疗, 但没有治疗在ESC期间(7%).
一些ESC之前和在ESC期间接受治疗(23%).
|
|
楼主: StephenW
发表于 2018-3-18 09:01
